Qiagen (NYSE:QGEN) Updates FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.280- for the period, compared to the consensus EPS estimate of 2.350. The company issued revenue guidance of $2.1 billion-, compared to the consensus revenue estimate of $2.1 billion. Qiagen also updated its Q1 2025 guidance to 0.500- EPS.

Qiagen Trading Up 0.9 %

QGEN stock traded up $0.40 on Wednesday, reaching $43.76. The company’s stock had a trading volume of 1,533,236 shares, compared to its average volume of 1,163,455. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The business has a fifty day simple moving average of $43.78 and a two-hundred day simple moving average of $43.25. The firm has a market cap of $9.71 billion, a PE ratio of 109.09, a PEG ratio of 3.10 and a beta of 0.36. Qiagen has a 12-month low of $40.15 and a 12-month high of $49.30.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. As a group, research analysts forecast that Qiagen will post 2.23 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on QGEN. Morgan Stanley reiterated an “equal weight” rating and set a $46.67 target price (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective for the company. in a research report on Thursday, October 17th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $52.50 price target (up from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.07.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.